Joined October 2014
- Tweets705
- Following414
- Followers875
- Likes2.1K
NAPOLI-3 positive. Historical retrospective data suggests no difference in survival between FOLFIRINOX and gem abraxane. Maybe naliri isn’t the same as iri? Looking forward to see data. @GIcancerDoc ipsen.com/us/blog/press-rele…
Thank you for the opportunity to speak at this event for this great endeavor! @GIcancerDoc @MayoCancerCare
Next up at @KRASKickers Connect Patient conference today.
Targeting KRAS: From the
“Undruggable” to Druggable in Colorectal Cancer
Daniel Ahn, D.O. , M.S. , Mayo Clinic
@the_danielahn @MayoClinic
Daniel Ahn retweeted
“Given that olaparib is expensive and relatively toxic, and in the absence of a clear survival benefit, it may be difficult to justify its use”
Daniel Ahn retweeted
It is time we started treating radiation as experimental therapy in pancreatic cancer and found a way to prove its utility. I still use it where I believe it helps--such things as clearing margins and getting people time off systemic therapy, but would be nice to prove benefit
"In conclusion, there is very little evidence to support the use of radiotherapy in nonmetastatic #pancreaticcancer. Further exploratory studies may define a role in a select subgroup of patients with borderline resectable and locally advanced disease ...."
Our editorial on A021501. Do we really need radiation in PDAC? Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer | Gastroenterology | JAMA Oncology | JAMA Network @MayoCancerCare @GIcancerDoc jamanetwork.com/journals/jam…
Our review highlighting tucatinib in HER-2 mCRC.
Ongoing MOUNTANEER trial through @accru__network led by @GIcancerDoc and John Strickler investigating its efficacy in mCRC @MayoCancerCare
tandfonline.com/doi/full/10.…
Open across the country at academic and community centers @MayoCancerCare @accru__network
Phase II REVERCEII ACCRU-GI-1809 Daniel Ahn, DO @the_danielahn @mayoclinic @gicancerdoc #ASCOGI22 #GI22 #GICancer #mCRC #Research
oncologytube.com/video/40643…
ALT Phase II REVERCEII ACCRU-GI-1809 Daniel Ahn, DO @the_danielahn @mayoclinic @gicancerdoc #ASCOGI22 #GI22 #GICancer #mCRC #Research
HIMALAYA. If D is non inferior to S, T+D similar to D, is T needed? “Is the juice (toxicities) worth the squeeze?” Or is it better than atezo/bev? For patients with a contraindication to anti-angiogenic therapy, D (or T+D 😬) would be an appropriate first-line therapy in HCC.
While not their in person, watching and supporting colleague and friend presenting exciting data with MRTX849. Never too early to start! @MayoCancerCare @GIcancerDoc #ascogi22
Yes, excited to have a good friend and even better physician join our group!!!We’re lucky to have @WuGiOnc
Super-excited to share the fantastic news that the incredibly talented @WuGiOnc will be joining our #gicancer program @MayoCancerCare in #Arizona to lead our #gicancer research program ! Start date -- Feb 2022 !
Great talk to learn in-person from KOLs and friends! @GIcancerDoc
How it started and how it’s going in #biliarycancer @rachnatshroff @DrElkhoueiry cochairs with @the_danielahn precision medicine is NOT for everyone @ISGIOofficial @gotoPER @uarizona @UCSDHealth @MayoCancerCare
Daniel Ahn retweeted
Incidence of #cholangiocarcinoma are rising as second most prominent #hcc #rarecancersday says @the_danielahn with chairs @DrElkhoueiry @rachnatshroff @ISGIOofficial @gotoPER @MayoCancerCare @UCSDHealth @uarizona
Great work from Mansi Arora and collaborators, now leading to an approved IIT to open shortly across all three Mayo Clinic sites. Hopefully results will lead to a reconsideration for a NCI CTEP Coop study in the future! @MayoCancerCare @curecc @staclinds @EileenMOReilly
Great work from @MiteshBorad lab @MayoCancerCare supporting @the_danielahn clinical study with Gem/Cis/Abemaciclib in 1L #cholangiocarcinoma with support in part by HB SPORE
Synergism w Chemotherapy + CDK 4/6 Inhibitors in #cholangiocarcinoma @curecc
pubmed.ncbi.nlm.nih.gov/3440…
Daniel Ahn retweeted
A not to miss conference in #Miami (with a virtual option)! Everything you need to know about #gastrointestinal #cancer ! Fantastic lineup of speakers and loads of fun learning ..
@YJanjigianMD @DocCatenacci @KristenCiombor @the_danielahn @WuGiOnc @JavleMilind @rachnatshroff
Hear debate-style presentations on emerging clinical questions in GI oncology.
Reserve your seat now for this highly engaging conference: bit.ly/3AsnljG
Daniel Ahn retweeted
Register now! @GIcancerDoc of @MayoClinic AZ will chair our GI Malignancies IPC with LIVE Q&A on 6/16 at 630pm AZ Time. #oncliveIPC @OncLiveSOSS @donnashort To learn more, register here: ow.ly/H4eG50EATuc
Can’t wait!
.@GIcancerDoc of @MayoClinic will chair an @OncLiveSOSS GI Malignancies IPC with LIVE Q&A on 6/16 at 630pm AZ Time. Register now: bit.ly/3aYrqle #oncliveIPC @donnashort @the_danielahn @Jcj84Jeremy @sonbol_bassam #pancsm #HepatocellularCarcinoma #crcsm #GastricCancer
After yest FDA ODAC mtg, hearing the argument that the lack of benefit in KN240 was that it was underpowered. Are we really justifying a drug with incremental benefit should be used bc placebo did too well/over performed? We can do better for our pts @GIcancerDoc @VPrasadMDMPH
Agree 💯 %. Additionally, the clinical benefit for pembro is in a small subset of patients, with no biomarker available for selection. It could not beat placebo. If there were no other therapies available, one could argue. But with agents that beat placebo (Cabo, Rego, Ram) 🤦🏻♂️
Despite limited access due to CoVID-19, routine health maintenance is key. Several non-invasive options that can be done at home including Cologuard @MayoCancerCare @MayoClinic health.usnews.com/health-car…
